F., Breitenbuecher von Pawel J. M., Sebastian C., Kortsik S., Ting S., Kasper J., Wohlschläger K., Worm A., Morresi-Hauf A., Schad D., Westerwick B., Wehler M., Werner G., Munzert B., Gaschler-Markefski K.W., Schmid M., Schuler Supplementary Material for: Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536 Background: Polo like kinase 1 (PLK1) is frequently upregulated in tumors and is thus viewed as a promising therapeutic target in various cancers. Several PLK1 inhibitors have recently been developed and clinically tested in solid cancers, albeit with limited success. So far, no predictive biomarkers for PLK1 inhibitors have been established. To this end, we conducted a post-hoc biomarker analysis of tumor samples from non-small cell lung cancer (NSCLC) patients treated with the PLK1 inhibitor BI2536 in a phase II study. Methods: We analyzed formalin-fixed paraffin-embedded surplus tumor tissue from 47 study patients using immunohistochemistry (IHC) and DNA sequencing of KRAS, EGFR, BRAF, and PIK3CA. Results: KRAS-mutated patients showed numerically prolonged progression-free survival, but statistical significance was not established. Interestingly, when pathways rather than single genes were analyzed, a positive correlation between IHC staining of activated ERK (p-ERK) and mutated KRAS was detected, whereas KRAS mutation status was found to be negatively correlated with activated AKT (p-AKT). Conclusion: With this hypothesis-generating study in BI2531-treated patients, we could not establish a correlation between KRAS mutations and relevant clinical endpoints. Future clinical trials with concomitant systematic biosampling and comprehensive molecular analyses are required to identify biomarkers predictive for response to PLK1 inhibitors. NSCLC;BI2536;KRAS;Lung cancer;PLK1 2017-06-20
    https://karger.figshare.com/articles/figure/Supplementary_Material_for_Comprehensive_Biomarker_Analyses_in_Patients_with_Advanced_or_Metastatic_Non-Small_Cell_Lung_Cancer_Prospectively_Treated_with_the_Polo-Like_Kinase_1_Inhibitor_BI2536/5120320
10.6084/m9.figshare.5120320.v1